Clinical experience with linezolid for the treatment of orthopaedic implant infections

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue SUPPL1, 2014, Pages

  Morata, Laura ^a   Tornero, Eduard ^b   Martínez Pastor, Juan C ^b   García Ramiro, Sebastián ^b   Mensa, Josep ^a   Soriano, Alex ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Gram positive cocci; Implant removal; Orthopaedic surgery; Prosthetic joint infection

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; LINEZOLID; OXAZOLIDINONE DERIVATIVE;

ANEMIA; CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROENTERITIS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMAN; OSTEOARTHRITIS; PATHOLOGY; PROSTHESIS-RELATED INFECTIONS; TREATMENT OUTCOME;

ACETAMIDES; ANEMIA; ANTI-BACTERIAL AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROENTERITIS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OSTEOARTHRITIS; OXAZOLIDINONES; PROSTHESIS-RELATED INFECTIONS; TREATMENT OUTCOME;

EID: 84906833671     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku252     Document Type: Article

References (38)

1. Moran E, Masters S, Berendt AR et al. Guiding empirical antibiotic therapy in orthopaedics: the microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect 2007; 55: 1-7.
2. Zimmerli W, Frei R, Widmer AF et al. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994; 33: 959-67.
3. Mittal Y, Fehring TK, Hanssen A et al. Two-stage reimplantation for periprosthetic knee infection involving resistant organisms. J Bone Joint Surg Am 2007; 89: 1227-31.
4. Kilgus DJ, Howe DJ, Strang A. Results of periprosthetic hip and knee infections caused by resistant bacteria. Clin Orthop Relat Res 2002: 116-24.
5. Salgado CD, Dash S, Cantey JR et al. Higher risk of failure of methicillinresistant Staphylococcus aureus prosthetic joint infections. Clin Orthop Relat Res 2007; 461: 48-53.
6. Walls RJ, Roche SJ, O'Rourke A et al. Surgical site infection with methicillin-resistant Staphylococcus aureus after primary total hip replacement. J Bone Joint Surg Br 2008; 90: 292-8.
7. Ferry T, Uckay I, Vaudaux P et al. Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection. Eur J Clin Microbiol Infect Dis 2010; 29: 171-80.
8. Jones RN, Ross JE, Fritsche TR et al. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006; 57: 279-87.
9. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 2003; 51 Suppl 2: ii9-16.
10. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 Suppl 2: ii17-25.
11. Kutscha-Lissberg F, Hebler U, Muhr G et al. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003; 47: 3964-6.
12. Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46: 2723-6.
13. Attassi K, Hershberger E, Alam R et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34: 695-8.
14. Nukui Y, Hatakeyama S, Okamoto K et al. High plasma linezolid concentration and impaired renal function affect development of linezolidinduced thrombocytopenia. J Antimicrob Chemother 2013; 68: 2128-33.
15. Matsumoto K, Takeshita A, Ikawa K et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 2010; 36: 179-81.
16. Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004; 79: 1137-44.
17. Senneville E, Legout L, Valette M et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28: 1155-63.
18. Bassetti M, Vitale F, Melica G et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 2005; 55: 387-90.
19. Soriano A, Gomez J, Gomez L et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis 2007; 26: 353-6.
20. Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007; 59: 173-9.
21. Vercillo M, Patzakis MJ, Holtom P et al. Linezolid in the treatment of implant-related chronic osteomyelitis. Clin Orthop Relat Res 2007; 461: 40-3.
22. Oussedik SI, Haddad FS. The use of linezolid in the treatment of infected total joint arthroplasty. J Arthroplasty 2008; 23: 273-8.
23. Papadopoulos A, Plachouras D, Giannitsioti E et al. Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study. J Chemother 2009; 21: 165-9.
24. Gomez J, Canovas E, Banos V et al. Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant. Antimicrob Agents Chemother 2011; 55: 4308-10.
25. Nguyen S, Pasquet A, Legout L et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009; 15: 1163-9.
26. Harwood PJ, Talbot C, DimoutsosMet al. Early experience with linezolid for infections in orthopaedics. Injury 2006; 37: 818-26.
27. Bejon P, Berendt A, Atkins BL et al. Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology. J Antimicrob Chemother 2010; 65: 569-75.
28. Hsieh PH, Huang KC, Lee PC et al. Two-stage revision of infected hip arthroplasty using an antibiotic-loaded spacer: retrospective comparison between short-term and prolonged antibiotic therapy. J Antimicrob Chemother 2009; 64: 392-7.
29. Zmistowski B, Fedorka CJ, Sheehan E et al. Prosthetic joint infection caused by gram-negative organisms. J Arthroplasty 2011; 26: 104-8.
30. Barberan J, Aguilar L, Carroquino G et al. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med 2006; 119: 993 e7-10.
31. Senneville E, Joulie D, Legout L et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011; 53: 334-40.
32. Lora-Tamayo J, Murillo O, Iribarren JA et al. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis 2012; 56: 182-94.
33. Vilchez F, Martinez-Pastor JC, Garcia-Ramiro S et al. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement. Clin Microbiol Infect 2011; 17: 439-44.
34. Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 1537-41.
35. Legout L, Valette M, Dezeque H et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? J Antimicrob Chemother 2010; 65: 2224-30.
36. Gandelman K, Zhu T, Fahmi OA et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2011; 51: 229-36.
37. Hoyo I, Martinez-Pastor J, Garcia-Ramiro S et al. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis 2012; 44: 548-50.
38. Pea F, Viale P, Cojutti P et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012; 67: 2034-42.